Blood cell analyzers are commercially used in laboratory settings for
characterizing various components of blood, notably complete blood
count and differential counts, for the detection of various
blood-related disorders and several common physiological indications.
The wide application of blood analysis for diagnosing indications
such as anemia, diabetes, autoimmune disorders, and cancer is
boosting the evolution of the market. The rapid evolution of
automated cell counters that incorporates a large number of analysis
parameters into a single instrument platform with the ability to
offer rapid results is a notable development catalyzing the growth of
the market. In recent years, the market has witnessed the advent of
diagnostic point-of-care analyzers that offer reliable precise
results, thereby facilitating faster treatment. Advancement in
chemical reagents and physical technologies used in blood cell
analyzers bodes well for the market.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=33728
The global blood cell analyzer market is estimated to rise from
US$1,364.2 Mn in 2017 to reach a worth of US$1,844.9 Mn by end of
2022. The market is anticipated to clock a CAGR of 6.2% from 2017 to
2022.
The growing demand for hematology analyzers for the detection of
several common blood-related disorders in various clinical settings
is a key factor driving the market. The growing use of blood cell
analyzers in diagnosing blood transfusion-transmitted infections
world over is a key factor accentuating the market. The rise in
number of blood donations in a number of developing and developed
countries is a prominent trend bolstering the demand for blood cell
analyzers in these regions. In addition, the vastly emerging
application of blood cell analyzers in the assessment of
cardiovascular diseases and in the classification of bone marrow
disorders are key trends boosting the market.
However, the high cost of automated instruments has hampered their
adoption in several less developed nations. Nevertheless, the demand
for high-quality solutions for improving the laboratory workflow and
enhancing customer patient care is expected to stimulate advancement
in automated blood cell analyzers. The innovative use of reagents and
substantial advances in flow cytometry by manufacturers bodes well
for the market. Furthermore, the search for novel plasma-based
therapeutics is expected to unlock exciting opportunities for market
players in the coming years.
Read Report Overview @
http://globenewswire.com/news-release/2017/11/06/1174895/0/en/Blood-Cell-Analyzer-Market-to-Reach-a-US-1-844-9-Million-by-2022-End-Transparency-Market-Research.html
The intensifying need for high-performing, automated analyzers that
can provide high-throughput analysis with reduces turnaround time is
a notable aspect expected to open up exciting avenues for market
players in various regions. Recent advancements in automated cell
counters and sensor technology has considerably minimized the error
in the functioning of blood cell analyzers.
Geographically, North America holds the major share, vis-à-vis
revenue, of the global market and is expected to account to lead
throughout the assessment period. The opportunities in the regional
market is projected to reach US$717.5 Mn by 2022 end. The dominance
of the regional market is attributed mainly to the vastly rising
demand for advanced semi- and fully-automated blood cell analyzers in
various clinical settings. Of all the product type, fully automated
biochemistry analyzers is the leading segment and is anticipated to
retain its dominance for the next few years as well. The segment is
projected to hold a whopping share of 80.0% by the end of 2022.
Several emerging and leading players are launching comprehensive and
advanced solutions with new applications for different clinical
settings, with a move to consolidate their shares in various regions.
Some of the leading players operating in the market are Sysmex
Corporation, Abbott Laboratories, Danaher Corporation, Siemens
Healthcare, Horiba Ltd, Bio-Rad Laboratories, Inc., F. Hoffmann-La
Roche AG, Sigma Aldrich, and Boule Diagnostics AB.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=33728
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment